Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234567 · ClinicalTrials.gov registry record
A Prospective Sub-Study of the Global Hypophosphatasia Registry
A clinical trial of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 30
- Enrollment target
- 12
- Study locations
NCT05234567: Recruiting study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
NCT05234567 is a study of Hypophosphatasia that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 30 participants, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05234567, a study of Hypophosphatasia, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 12
- Study locations
Study Summary
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
Primary Outcome
This will be based on clinical and biochemical assessments as well as positive anti-drug antibodies and positive neutralizing antibodies.
Conditions Studied
Interventions
- BIOLOGICAL Asfotase Alfa
Study Locations (12)
Ohio
- Clinical Trial Site - Cincinnati
- Clinical Trial Site - Columbus
Connecticut
- Clinical Trial Site - Hartford
Illinois
- Clinical Trial Site - Chicago
Massachusetts
- Clinical Trial Site - Boston
Missouri
- Clinical Trial Site - Kansas City
New York
- Clinical Trial Site - Mineola
Pennsylvania
- Clinical Trial Site - Pittsburgh
Tennessee
- Clinical Trial Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2028-07-18 |
What NCT05234567 shows while recruiting
NCT05234567 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 1 intervention - of which Asfotase Alfa is the first listed.
NCT05234567 lists 12 locations in 11 states (Ohio, Connecticut, Illinois).
Frequently Asked Questions
What is clinical trial NCT05234567 about?
NCT05234567 is a clinical study titled "A Prospective Sub-Study of the Global Hypophosphatasia Registry". In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
What is the current status of trial NCT05234567?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2022-08-25. Estimated completion is 2028-07-18.
What conditions does trial NCT05234567 study?
This clinical trial studies the following conditions: Hypophosphatasia.
What interventions are being tested in trial NCT05234567?
The interventions under investigation include: Asfotase Alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT05234567?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05234567 being conducted?
This trial has 12 study locations across Connecticut, Illinois, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
United States Hypophosphatasia Molecular Research Center
RECRUITING
-
Natural History Study of Patients With Hypophosphatasia (HPP)
RECRUITING
-
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI